COMP <GO>
XGN vs KEQU // PIOTROSKI F-SCORE QUALITY
Exagen Inc. (NASDAQ) VS. Kewaunee Scientific Corporation (NASDAQ) • 15-METRIC TALLY: XGN 4
— KEQU 6
▲ PIOTROSKI F-SCORE QUALITY LEADER: KEQU
LAST: $8.59 (-1.26%) • MKT CAP: $210.8M
piotroski-score
4/9
LAST: $33.44 (-0.21%) • MKT CAP: $97.0M
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XGN VS. KEQU)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XGN | KEQU | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 58.30% | 28.50% | +29.80 | XGN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 16.70% | -51.70 | KEQU | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 6.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.77% | 19.20% | -25.97 | KEQU | /fcf-yield <GO> |
| Operating Margin | -21.10% | 5.90% | -27.00 | KEQU | /operating-margins <GO> |
| Net Profit Margin | -30.00% | 3.40% | -33.40 | KEQU | /net-margins <GO> |
| Revenue Growth (YoY) | 19.70% | 17.30% | +2.40 | XGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.37 | -3.17 | KEQU | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 8/9 | -4.00 | KEQU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.9 | 49.8 | +10.10 | XGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 8.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $210.8M | $97.0M | $113.7M | XGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XGN REV | KEQU REV | XGN GROSS % | KEQU GROSS % | XGN FCF | KEQU FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $66.6M | $282.0M | 58.3% | 28.5% | -$14.3M | $18.6M |
| FY 2024 | $55.6M | $240.5M | 59.5% | 28.6% | -$13.8M | $14.8M |
| FY 2023 | $52.5M | $203.8M | — | — | -$14.5M | $19.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XGN // BETA —
KEQU // BETA —